Dr. O'Reilly Discusses Advancements in Early-Stage Pancreatic Cancer

Eileen O'Reilly, MD
Published: Friday, Dec 15, 2017



Eileen O’Reilly, MD, associate director for clinical research at Memorial Sloan Kettering Cancer Center, discusses advances for patients with early-stage pancreatic cancer.

The major change for patients with early-stage pancreatic cancer is the combination of cytotoxic chemotherapy in the adjuvant setting. Data from ESPAC-4 study demonstrated that the addition of capecitabine to gemcitabine had an improvement in overall survival with low toxicity.
 


Eileen O’Reilly, MD, associate director for clinical research at Memorial Sloan Kettering Cancer Center, discusses advances for patients with early-stage pancreatic cancer.

The major change for patients with early-stage pancreatic cancer is the combination of cytotoxic chemotherapy in the adjuvant setting. Data from ESPAC-4 study demonstrated that the addition of capecitabine to gemcitabine had an improvement in overall survival with low toxicity.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Moving Forward From the Status Quo for the Treatment of Soft Tissue Sarcoma: Key Questions and New Answers to Optimize OutcomesOct 31, 20182.0
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Publication Bottom Border
Border Publication
x